CLINICAL NEWS
About the Meeting
ASH Meeting on Hematologic
Malignancies
September 17—19, 2015
Fairmont Chicago, Millennium Park,
Chicago, IL
At the inaugural ASH Meeting on Hematologic Malignancies, top experts in
core malignancies will share their own
evidence-based treatment approaches
through specialized “How I Treat”
presentations, in everything from special cases in CML to to Waldenstrom
macroglobulinemia.
that the best way to convey the optimal use of
these agents is through examples from real-life
practice. The case-based format we’ve chosen
means practitioners can really appreciate how
to integrate these new advances into their own
practice.
Are there any sessions that you consider
“can’t-miss?”
Dr. Connors: We organized the meeting to allow
people to attend all the sessions – so they hopefully
won’t have to worry about missing any! Attendees
will be able to see presentations of diseases that
they commonly encounter, but also the full range
of hematologic malignancies. We thought it was
important to give physicians the opportunity to
understand what is going on in the areas that they
don’t see as frequently in the clinic, but which they
should remain abreast of.
Dr. Anderson: The sessions are divided according
to the disease states – lymphoid and myeloid
To review the information being
shared, presenters will also participate
in panel discussions periodically
throughout the two-day program,
including:
• Lymphoma Panel Discussion I
(Joseph M. Connors, MD; Oliver W. Press,
MD, PhD; Jonathan Friedberg, MD)
Friday, September 18, 9:30 AM
THE FIRST AND ONLY rFVIII WITH A PROLONGED HALF-LIFE
• CML/MPN Panel Discussion
(Michael J. Mauro, MD; Neil P. Shah, MD,
PhD; Ruben A. Mesa, MD)
Friday, September 18, 11:00 AM
• Myeloma Panel Discussion I
(Faith Davies, MD; Steven Treon, MD, PhD)
Friday, September 18, 2:30 PM
• Myeloma Panel Discussion II
(Irene Ghobrial, MD; Antonio Palumbo, MD;
Kenneth C. Anderson, MD)
Friday, September 18, 5:30 PM
• MDS Panel Discussion
(David P. Steensma, MD; H. Joachim Deeg, MD)
Saturday, September 19, 8:40 AM
• AML Panel Discussion
(Martin S. Tallman, MD; Ross Levine, MD;
Frederick Appelbaum, MD)
Saturday, September 19, 11:40 AM
• ALL Panel Discussion
(Richard A. Larson, MD; Wendy Stock, MD;
Adele K. Fielding, MBBS, PhD)
71%
OF HTCs* HAVE
PRESCRIBED
ELOCTATE†
Find out more at
ELOCTATEpro.com
Saturday, S